Vytrus Biotech, S.A. (BME:VYT)

Market Cap	126.41M +483.3%
Revenue (ttm)	8.09M +54.4%
Net Income	1.95M +180.2%
EPS	n/a
Shares Out	7.52M
PE Ratio	64.75
Forward PE	35.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,270
Average Volume	13,299
Open	17.00
Previous Close	17.00
Day's Range	16.80 - 17.40
52-Week Range	2.84 - 18.80
Beta	-0.14
RSI	65.50
Earnings Date	Apr 9, 2026

About Vytrus Biotech

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. The company offers Clarivine that activates skin’s regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum that brightens skin, whitens dark spots, evens skin tone, and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 37
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: VYT

Financial Performance

In 2024, Vytrus Biotech's revenue was 6.09 million, an increase of 29.51% compared to the previous year's 4.70 million. Earnings were 1.02 million, an increase of 87.36%.